14.90 0.00 (0.00%)
After hours: 4:37PM EDT
|Bid||14.70 x 800|
|Ask||14.90 x 100|
|Day's Range||14.55 - 15.90|
|52 Week Range||4.45 - 19.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.33|
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist healthcare fund investment substantiates the ORGS growth opportunity. Demand for CDMOs, like ORGS, is growing as more cell therapies (like gene therapies and CAR-T cells) come to market in the coming years.
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
“The dosing of the first patient with lifileucel in Europe for the treatment of metastatic melanoma marks an important milestone for Iovance and our global development plans as our European Union (EU) manufacturing is now able to support enrollment in that region,” said Dr. Maria Fardis, PhD, MBA, president and chief executive officer of Iovance Biotherapeutics. In December 2017, the company announced that the Generation 2 manufacturing process, with a duration of 22 days, was selected and all studies were shifted to utilize that method of manufacturing. The company has manufacturing capability in both the US and EU. This is the first patient treated with TIL developed in an EU-based manufacturing facility.
Iovance Biotherapeutics Inc’s (NASDAQ:IOVA): Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicateRead More...
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
SAN CARLOS, Calif., May 31, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ServisFirst ...
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a research collaboration deal with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance") to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs), for use in the treatment of cancer.
Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.
RXi reported revenues of $23,000 for the quarter from grants related to BioAxone’s work in spinal cord injury, compared to zero in revenues in 1Q:17. Following the availability of the trial results, RXi will set up data rooms for interested buyers.
The San Carlos, California-based company said it had a loss of 31 cents per share. Losses, adjusted for stock option expense, came to 26 cents per share. The results beat Wall Street expectations. The ...
-Company to Host Conference Call at 4:30pm ET Today-. SAN CARLOS, Calif., May 10, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating ...
SAN CARLOS, Calif., May 03, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
Morphogenesis is part of the burgeoning life science sector that state and local economic development officials want to expand. It’s one of at least three companies establishing offices that are near Moffitt, a national leader in cancer treatment.
SAN CARLOS, Calif., May 02, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. Losses, adjusted for stock option expense, came to 32 cents per share. The results met Wall Street expectations. ...
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Iovance Biotherapeutics Inc (NASDAQ: IOVA ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern ...
SAN DIEGO , March 6, 2018 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc., as detailed ...